Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

@article{Vogel2006EffectsOT,
  title={Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.},
  author={Victor G Vogel and Joseph P. Costantino and D. Lawrence Wickerham and Walter M. Cronin and Reena S Cecchini and James Norman Atkins and Therese Bartholomew Bevers and Louis Fehrenbacher and Eduardo R. Pajon and James L. Wade and André Robidoux and Richard G. Margolese and Joan James and Scott M. Lippman and Carolyn D Runowicz and Patricia A. Ganz and Steven E. Reis and Worta McCaskill-Stevens and Leslie G Ford and Virgil Craig Jordan and Norman Wolmark},
  journal={JAMA},
  year={2006},
  volume={295 23},
  pages={
          2727-41
        }
}
CONTEXT Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis. OBJECTIVE To compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast cancer and other disease outcomes. DESIGN, SETTING, AND PATIENTS The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial, a prospective, double-blind… Expand
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
TLDR
Raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically significant higher risk of noninvasive breast cancer. Expand
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
TLDR
No significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health, mental health, and depression, although the tamxifen group reported better sexual function. Expand
Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
  • V. Vogel
  • Medicine
  • Clinical interventions in aging
  • 2008
TLDR
The effect of raloxifene on invasive breast cancer was, therefore, equivalent to that of tamoxifen with more favorable rates of adverse effects including uterine malignancy and clotting events. Expand
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
TLDR
Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxfene in preventing noninvasive disease, with far less toxicity. Expand
Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.
TLDR
This analysis suggests a persistent effect for breast cancer risk reduction in patients who discontinued raloxifene, although this conclusion is limited by the small sample size. Expand
The use of tamoxifen and raloxifene for the prevention of breast cancer.
TLDR
The NSABP Study of Tamoxifen and Raloxifene in a population of healthy postmenopausal women at increased risk for breast cancer to determine the relative effects on the risk of invasive breast cancer. Expand
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
TLDR
An extended follow-up of the Italian Randomized Tamoxifen Prevention Trial shows that appropriate selection of women at high risk for hormone receptor-positive (HR+) disease may improve the risk-benefit ratio of tamoxIFen intervention. Expand
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
TLDR
Raloxifene reduces risk of invasive ER-positive breast cancer regardless of a woman's baseline breast cancer risk but does not reduce risk of noninvasive or ER-negative breast cancers. Expand
Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk
TLDR
Raloxifene therapy was associated with a reduced risk of invasive breast cancer in postmenopausal women irrespective of the presence/absence of risk factors; its effect was greater in women with a family history of breast cancer. Expand
Moving forward with breast cancer prevention
TLDR
Rather than using a ‘‘one size fits all’’ approach to chemoprevention, this work proposes following the cardiovascular disease paradigm in which interventions are targeted according to the estimated risk of disease development. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 71 REFERENCES
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
TLDR
The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast cancer. Expand
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
TLDR
No significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health, mental health, and depression, although the tamxifen group reported better sexual function. Expand
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
TLDR
Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe. Expand
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
TLDR
The proposed NSA BP B-35 trial will have the same design as NSABP B-24 but will compare tamoxifen with anastrozole in postmenopausal women, and outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Expand
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
TLDR
It is concluded that raloxifene continues to reduce the risk of breast cancer in women with osteoporosis after 4 years of treatment, through prevention of new cancers or suppression of subclinical tumors, or both. Expand
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
TLDR
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease. Expand
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
TLDR
The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis, and no new safety concerns related to ral oxifene therapy were identified during CORE. Expand
Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
TLDR
Raloxifene therapy reduces breast cancer risk in postmenopausal osteoporotic women regardless of lifetime estrogen exposure, but the reduction is greater in those with higher lifetime exposure to estrogen. Expand
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
TLDR
Prophylactic use of tamoxifen is contraindicated in women at high risk of thromboembolic disease and the combined evidence indicates that mortality from non-breast-cancer causes is not increased by tamoxIFen. Expand
Overview of the main outcomes in breast-cancer prevention trials
TLDR
Although tamoxifen cannot yet be recommended as a preventive agent (except possibly in women at very high risk with a low risk of side-effects), continued follow-up of the current trials is essential for identification of a subgroup of high-risk, healthy women for whom the risk-benefit ratio is sufficiently positive. Expand
...
1
2
3
4
5
...